Idorsia is engaged in the discovery, development, and commercialization of innovative medicines to help patients.

Idorsia

IPhone / Mobile Compatible

Viewport Meta

Domain Not Resolving

SSL by Default

Google Tag Manager

Apple Mobile Web Clips Icon

HSTS

Google Font API

Google Analytics

Associate General Counsel, US

Justin Drinkwine

Vice President - Head of US Finance & Infrastructures

Bill Gileza

Vice President, Head of US Drug Regulatory Affairs

Brian Schlag

Vice President | US Head of Sales

Joanna Stevens

Vice President, Head of Marketing US

Michael Moye

Business Management

Scotty Bowman

Director, Compliance Auditing & Monitoring

Aaron Maskery

Head of US Medical Affairs

Ajay Ahuja, MD, MBA

Country Medical Director

Alistair Paice

Director, Corporate Accounts

Amy Holden

Mike Ufer

Senior Director Clinical Pharmacology

André C Muller

EVP, Chief Financial Officer

Martine Clozel

Executive Vice President, Chief Scientific Officer

Jon Fuller

Scientific Software Developer

Jean-Paul Clozel

Santhera Pharmaceuticals develops and markets pharmaceutical products for the treatment of mitochondrial and neuromuscular diseases.

Europe, Middle East, and Africa (EMEA) Female Founded Investors

Health Care Companies With More Than 1000 Employees (Top 10K)

Europe Companies With More Than $100M in Revenue (Top 10K)

Europe Companies With More Than 1000 Employees (Top 10K)

The purpose of Idorsia is to discover, develop and commercialize innovative medicines to help more patients.  We have more ideas, we see more opportunities and we want to transform the horizon of therapeutic options.   In order to achieve this, we will develop Idorsia into a leading biopharmaceutical company, with a strong scientific core.  Headquartered in Switzerland – a biotech-hub of Europe – Idorsia is a high-potential biopharmaceutical company, specialized in the discovery, development and commercialization of innovative small molecules, with the aim of transforming the horizon of therapeutic options.

Post-IPO Debt - Idorsia

Post-IPO Equity - Idorsia

Grant - Idorsia

CARB-X

Allschwil

Basel-Landschaft

Switzerland

Europe

Idorsia teases Tryvio global licensing deal while planning to lay off 270 staff

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Idorsia enters into exclusive negotiations for global rights to aprocitentan

Swiss pharma firm Idorsia plans debt restructuring, job cuts

Idorsia's once-daily TRYVIO™ (aprocitentan) is now available in the U.S., advancing treatment options for millions of patients with difficult-to-control hypertension

Idorsia is advancing the treatment of hypertension with new data at the 2024 American Heart Association (AHA) Scientific Sessions

Idorsia announces financial results for the first nine months of 2024

Amended terms of Idorsia’s 2024 convertible bonds become effective

Idorsia announces financial results for the first half 2024

United Kingdom

United States

North America

Canada

India

Asia

HTML5

Apache Server

Bootstrap

Google Fonts

Amazon EC2

Vimeo

Office 365

Microsoft Outlook

Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.

Idorsia Ltd

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Sep 27, 2024 3:39 PM	af1d6af7
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Sep 27, 2024 3:39 PM	0e5dc998
crunchbase trigger	general	Nov 27, 2024 12:50 PM	b2f7c234
crunchbase profile	general	Nov 28, 2024 1:52 AM	b9582893
li profile	general
translate crunchbase fundingrounds	general	Nov 28, 2024 3:23 AM	598752b1
peers	general	Sep 27, 2024 3:39 PM	9e355eff
news basic	general	Sep 27, 2024 3:39 PM	9ebdad5b
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:IDORSIA

Idorsia

Last Close

0.77

25/11 09:15

Market Cap

273.49M

Beta: -

Volume Today

109.95K

Avg: -